This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Durata Therapeutics Adds Independent Director Lisa M. Giles To The Company’s Board

Durata Therapeutics (NASDAQ: DRTX) today announced that, as contemplated by the prospectus related to the company’s initial public offering, the company’s board of directors appointed a new independent director to the board to replace one of the company’s existing directors who is transitioning off the board. The board has appointed Lisa Giles, CEO & President of Giles & Associates and former Vice President of Strategy and Development at G.D. Searle & Company, as an independent director, effective August 3, 2012. Ms. Giles is replacing George F. Horner, III, who will be transitioning off of Durata’s board of directors, also effective August 3.

“The company and the board want to thank George for his valuable service and support since Durata’s founding in 2009, and we wish him continued success,” said Richard U. De Schutter, Chairman of the Durata board of directors. “We also welcome Lisa to the Durata board. Her background and experience in strategic planning and advising senior teams will add considerably to our deliberations as we draw closer to becoming a commercial stage company and look to expand our portfolio in the future.”

Ms. Giles is CEO and President of Giles & Associates Consultancy, which she formed in 2000. Prior to this, she was Vice President of Strategy and Development for G.D. Searle & Company, where she oversaw global pharmaceutical strategic planning, portfolio decision analysis, portfolio optimization and transaction analysis. Previously, Ms. Giles was Partner in the Healthcare Practice at Business Strategy Consulting and held positions of increasing responsibility at Abbott Laboratories in marketing, strategic planning and business development. She also is a trustee on the board of Northwestern Memorial Hospital Foundation. Ms. Giles completed the executive management program at Stanford University and The University of Chicago and holds a BS degree from Juniata College.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs